Tyra Biosciences Quarterly Balance Sheet
NASDAQ: TYRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Tyra Biosciences financial position
As of Jun 30, 2026, Tyra Biosciences reported total assets of $383.4 million, up 19.2% from a year earlier against total liabilities of $29.7 million. Shareholders' equity stood at $353.7 million, or 92.3% of assets. The company held $73.8 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 14.91, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Tyra Biosciences balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 73.83M | 84.95M | 77.39M | 61.95M | 98.49M | 100.72M | 91.97M | 103.89M | 99.49M | 254.37M | 58.01M | 215.65M |
| Total Current Assets | 366.97M | 394.61M | 265.45M | 281.22M | 302.15M | 324.57M | 347.46M | 365.61M | 378.57M | 390.78M | 211.67M | 224.63M |
| Property, Plant & Equipment | 1.17M | 1.22M | 1.31M | 1.35M | 1.41M | 1.52M | 1.65M | 1.79M | 1.90M | 1.59M | 1.63M | 1.15M |
| Total Assets | 383.36M | 412.04M | 282.61M | 301.85M | 321.50M | 343.48M | 363.56M | 380.59M | 392.46M | 404.74M | 225.86M | 238.36M |
| Accounts Payable | 2.33M | 3.64M | 1.18M | 1.99M | 2.25M | 2.50M | 590.00K | 1.17M | 1.58M | 2.88M | 4.66M | 2.31M |
| Total Current Liabilities | 24.62M | 19.26M | 18.09M | 15.88M | 13.77M | 14.25M | 14.59M | 12.37M | 10.38M | 8.72M | 15.33M | 10.15M |
| Total Liabilities | 29.70M | 24.46M | 23.43M | 21.34M | 19.35M | 19.94M | 20.41M | 18.30M | 16.42M | 14.86M | 21.59M | 16.19M |
| Shareholders' Equity | 353.66M | 387.57M | 259.18M | 280.51M | 302.15M | 323.53M | 343.15M | 362.29M | 376.04M | 389.88M | 204.26M | 222.17M |
| Retained Earnings | -456.12M | -410.56M | -371.26M | -337.42M | -307.56M | -279.46M | -251.31M | -225.74M | -201.72M | -183.02M | -164.83M | -142.00M |
| Net Cash (Debt) | 73.83M | 84.95M | 77.39M | 61.95M | 98.49M | 100.72M | 91.97M | 103.89M | 99.49M | 254.37M | 58.01M | 215.65M |
| Shares Outstanding | 59.66M | 59.47M | 53.71M | 53.32M | 53.23M | 53.09M | 50.75M | 52.87M | 52.74M | 52.47M | 43.02M | 42.93M |
This table shows 12 quarterly periods of Tyra Biosciences's balance sheet, from Q2 2026 back to Q3 2023, across 11 line items including cash & equivalents, total current assets, property, plant & equipment. Values in USD; B = billions, M = millions. Fiscal periods follow TYRA's reporting calendar. What is a balance sheet?